FCF YoY
-4.85%
OCF YoY
-4.59%
Capex Change
+385.0K
FCF Conversion Δ
—
Free cash flow bridge for Tango Therapeutics (TNGX) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: −$6.59M
FCF bridge breakdown for Tango Therapeutics (TNGX) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | −$135.95M | — |
| Operating Cash Flow | −$6.21M | -94.2% |
| Capital Expenditure | −$385.00K | -5.8% |
| Free Cash Outflow | −$142.54M | — |
- Prior Free Cash Flow−$135.95M
- Operating Cash Flow−$6.21M
- Capital Expenditure−$385.00K
- Free Cash Outflow−$142.54M
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Tango Therapeutics (TNGX) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement